Related Experiment Video
Updated: Jul 4, 2026
06:17
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
Comment on "Serum Amyloid β Oligomer May Predict Treatment Response in Middle-Aged and Late-Life Patients With
1Family Medicine, Zagreb West Health Center, Zagreb, Croatia.
Neuropsychopharmacology Reports
|July 3, 2026
Abstract:
Serum Aβ oligomer positivity may indicate neurodegenerative vulnerability and may be associated with poorer antidepressant treatment response in middle-aged and late-life depression. Further validation using amyloid PET, tau biomarkers, standardized treatment protocols, and longitudinal cognitive follow-up is needed.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...